COVID-19 Vaccine Clinical Trial
Official title:
Phase 1 Study for the Determination of Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC, Given Twice Intramuscularly to Healthy Volunteers, in a Placebo Controlled Study Design.
The objective is to determine the safety and immunogenicity of two different strengths (3 µg and 6 µg) of an inactivated COVID 19 Vaccine compared to placebo so that to demonstrate the safety and efficacy in prophylaxis of COVID-19.
This is a double-blind, double dose, parallel, randomized vaccination study. Each subject will receive in random order a double intramuscular dose of ERUCOV-VAC 3 µg/0.5 ml Vaccine, ERUCOV-VAC 6 µg/0.5 ml Vaccine or 0.5 ml of placebo Vaccine according to a sequence determined by randomization, on Day 0 (1st vaccination) and Day 21 (2nd vaccination).In total 34 healthy subjects of both genders will be monitored for one year in total, after Day 43 the study will be unblinded and the volunteers who took placebo vaccine will be released from the study. The most important evaluation will be performed on Day 43 after the first vaccine dose. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05049226 -
Third Dose Vaccination With AstraZeneca or Pfizer COVID-19 Vaccine Among Adults Received Sinovac COVID-19 Vaccine
|
Phase 2 | |
| Recruiting |
NCT05998824 -
COVID-19 Vaccination Hesitancy in Adults With Sickle Cell Disease
|
N/A | |
| Recruiting |
NCT05097053 -
A Heterologous 3rd COVID-19 Vaccine of MVC-COV1901 to Evaluate Immunogenicity and Safety in Adults With ChAdOx1-nCov-19
|
Phase 4 | |
| Active, not recruiting |
NCT05463419 -
A Phase II/III Study of PIKA Recombinant SARS-CoV-2 Vaccine as a Booster Dose.
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT05293223 -
Phase IIB Study of Recombinant Novel Coronavirus Vaccine
|
Phase 2 | |
| Completed |
NCT05288231 -
Cardiac Manifestation in Adolescent After Pfizer COVID-19 Injection in Thailand
|
||
| Completed |
NCT04546841 -
Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults
|
Phase 1 | |
| Terminated |
NCT04963790 -
Enabling Family Physicians to Reduce Vaccine Hesitancy and Increase Covid-19 Vaccine Uptake
|
N/A | |
| Completed |
NCT05216601 -
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901 or MVC-COV1901(Beta) Against COVID-19
|
Phase 1 | |
| Completed |
NCT04566276 -
ChulaCov19 Vaccine in Healthy Adults
|
Phase 1/Phase 2 | |
| Completed |
NCT04915820 -
Iron and COVID-19 Vaccine Response
|
N/A | |
| Completed |
NCT05268679 -
Covid-19 Vaccine Response in Heart Transplant Recipients
|
||
| Completed |
NCT04898946 -
Serological Response to mRNA and Inactivated COVID-19 Vaccine in Health Care Workers in Hong Kong
|
||
| Recruiting |
NCT05869968 -
SCIVAX: Biomarkers of Immune Dysfunction and Vaccine Responsiveness in Chronic SCI
|
||
| Active, not recruiting |
NCT05197712 -
Evaluation of the Safety, Tolerability, and Reactogenicity of the Baiya SARS-CoV-2 Vax 2 Vaccine for COVID-19 Disease
|
Phase 1 | |
| Recruiting |
NCT05553743 -
Researchers at UC San Diego Are Learning About the Benefits of Human Milk and How it Influences Infant and Child Health
|
||
| Active, not recruiting |
NCT05188469 -
Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID and EG-COVARo in Healthy Adult Volunteers
|
Phase 1/Phase 2 | |
| Completed |
NCT04764422 -
Assess the Safety and Immunogenicity of NDV-HXP-S Vaccine in Thailand
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04838080 -
Safety and Immunogenicity of the Inactivated Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine Compared to Placebo
|
Phase 1 | |
| Recruiting |
NCT05822219 -
Vaccine Hesitancy in Black/African Americans With Rheumatic Diseases
|
N/A |